|Day's Range||0.495 - 0.520|
|52 Week Range||0.190 - 1.130|
|PE Ratio (TTM)||-4.09|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.69|
By John Vandermosten, CFA OTC:ONCYF Public Offering of Shares Strengthens Balance Sheet In late May, 2017, Oncolytics Biotech, Inc. (OTC:ONCYF) announced and priced 16.4 million units at CAD$0.70 per share ...
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
"Mr. de Guttadauro brings a breadth of industry knowledge, experience and relationships to the Company and we are excited that he has chosen to join us," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.